title: Two-stage revision arthroplasty of the hip for infection using an interim articulated Prostalac hip spacer: a 10- to 15-year follow-up study.
abstract: We report the outcome at ten to 15 years of two-stage revision for hip infection in 99 patients using the Prostalac articulated hip spacer system. All the patients were contacted to determine their current functional and infection status using the Oxford-12, Short form-12, and Western Ontario and McMaster University Osteoarthritis Index questionnaires. A total of 11 of the 99 patients had a further infection, of whom seven responded to repeat surgery with no further sequelae. The mean interval between the stages was five months (1 to 36). We were able to review 48 living patients, with a mean age of 72 years (46 to 86), 34 (71%) of whom provided health-related quality-of-life outcome scores. The mean follow-up was 12 years (10 to 15). The long-term success rate was 89% and with additional surgery this rose to 96%. The mean global Western Ontario and McMaster University Osteoarthritis Index score was 80.6 (sd 18.3). The mean Oxford-12 score was 74.0 (sd 22.3), and the mean Short form-12 score was 53.1 (sd 9.4) (mental) and 33.5 (sd 13.5) (physical). The mean satisfaction score was 90.5 (sd 15.3). Two-stage revision for hip infection using a Prostalac interim spacer offers a predictable and lasting solution for patients with this difficult problem.
authors.affiliation: Buckinghamshire Hospitals NHS Trust, Stoke Mandeville Hospital, Mandeville Road, Aylesbury HP21 8AL, UK. biring7@aol.co.uk
authors.forename: G S
authors.initials: GS
authors.lastname: Biring
authors.forename: T
authors.initials: T
authors.lastname: Kostamo
authors.forename: D S
authors.initials: DS
authors.lastname: Garbuz
authors.forename: B A
authors.initials: BA
authors.lastname: Masri
authors.forename: C P
authors.initials: CP
authors.lastname: Duncan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D019644:Arthroplasty, Replacement, Hip / Q000295:instrumentation* / Q000379:methods; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery*; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D005260:Female; D005500:Follow-Up Studies; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D016459:Prosthesis-Related Infections / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery*; D011788:Quality of Life; D012086:Reoperation / Q000379:methods; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D020099:Coated Materials, Biocompatible